Project archive

Scientists at Fraunhofer ITEM have brought their targeted metabolomics approaches to numerous projects in the areas of clinical and veterinary medical research, both within Germany and internationally.

For the BAuA project “Modular Exposure Models for OSH Risk Assessment in Chemical Safety” (MEMORA), Fraunhofer researchers created a complete model for estimating inhalation exposure from spray applications.

Fraunhofer ITEM and its partners are investigating whether and how “old” PVC can be integrated into the circular economy as part of the EU project REMADYL.

Alternative, new-approach methodologies (NAMs) combining human-relevant in-vitro methods and computational (in-silico) approaches hold much promise.

With the aim of identifying specific biomarkers for teratogenic effects at developmental stages, Fraunhofer ITEM researchers have developed an analysis pipeline in the CEFIC-LRI project ZET-O-MAP that links morphological changes with alterations in gene expression.

Starting in January 2019, 13 partners from 7 European countries, including research institutes, universities and small and medium-sized enterprises, have been collaborating in the Horizon 2020 project MDOT (Medical Device Obligations Taskforce). This project is being coordinated by Fraunhofer ITEM, with a grant size of 8.3 million euros and 5 years overall duration.

The RealWorld4Clinic project consortium develops a medical multi-sensor system (MySentinel) that will enable high-quality collection of real-life cardiorespiratory health data.

Researchers of the Fraunhofer ITEM have developed a system that optically detects neonatal breathing and releases the aerosol directly at the patient interface in a breath-triggered manner.

The focus of the Fraunhofer ITEM researchers in the ImmunAvatar project is on mimicking IBD. The use of both healthy tissue and tissue from IBD patients enables the identification of disease-specific differences, which can also be modulated in the model.

The Fraunhofer project FibroPaths® aims to enable rapid and safe development of antifibrotic drugs.